Recombinant Mouse TNFRSF17 / BCMA Protein (Fc tag)

Supplier: Elabscience Product Name: Recombinant Mouse TNFRSF17 / BCMA Protein (Fc tag) Catalog No. PKSM040939 Product Type: recombinant protein Size: 100 ug Activity: Protein Construction: A DNA sequence encoding the extracellular domain (Met 1-Thr 49) of mouse BCMA (NP_035738.1) precursor was fused with the Fc region of human IgG1 at the N-terminus. Sequence: Met 1-Thr 49 Fusion Tag: N-Fc Accession: NP_035738.1 Species: Mouse Expressed Host: HEK293 Cells Shipping Conditions: In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise. Purity: > 95 % as determined by SDS-PAGE Endotoxin: < 1.0 EU per ?g of the protein as determined by the LAL method Stability: Samples are stable for up to twelve months from date of receipt at -70?.Store it under sterile conditions at -20? to -80?. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles. Molecular Weight: 33.8 kDa Applied MM: 40 kDa Formulation: Lyophilized from sterile PBS, pH 7.4 Reconstitution: Please refer to the printed manual for detailed information. Background: Tumor necrosis factor receptor superfamily, member 17 (TNFRSF17), also known as B cell maturation antigen (BCMA) or CD269 antigen, is a member of the TNF-receptor superfamily. This receptor is preferentially expressed in mature B lymphocytes, and may be important for B cell development and autoimmune response. This receptor has been shown to specifically bind to the tumor necrosis factor (ligand) superfamily, member 13b (TNFSF13BBAFF), and to lead to NF-kappaB and MAPK8/JNK activation. TNFRSF17/BCMA/CD269 also binds to various TRAF family members, and thus may transduce signals for cell survival and proliferation. TNFRSF17/BCMA/CD269 is a receptor for TALL-1 and BCMA activates NF-kappaB through a TRAF5-, TRAF6-, NIK-, and IKK-dependent pathway. The identification of TNFRSF17 as a NF-kappaB-activating receptor for TALL-1 suggests molecular targets for drug development against certain immunodeficient or autoimmune diseases. TNFRSF17/BCMA is a target of donor B-cell immunity in patients with myeloma who respond to DLI. Antibody responses to cell-surface BCMA may contribute directly to tumor rejection in vivo.